- STP0404 is the only clinical safety proven HIV treatment candidate with a novel mechanism that can block HIV re-activation.
 

- STP0404 is expected to enter Phase 2a clinical trial in the US in 4Q 2022.

- STP0404 is the world's first AIDS treatment with an ALLINI (Allosteric Integrase Inhibitor) mechanism in human clinical trials. All competing drugs developed with the same mechanism failed in preclinical stage due to toxicity issues.